Gene-editing biotechs overvalue CRISPR technology, Regeneron's top scientist George Yancopoulos said. "It's not just about the simple, initial CRISPR technology and IP," Yancopoulos told Insider. The ...
Geulah Livshits, PhD, a Senior Research Analyst at Chardan covering biotech companies, with a focus on gene editing and oncology. Genome editing’s dazzling potential and stubborn challenges were both ...
From model development to testing innovative gene editing-based therapeutic approaches, Lobna Elkhadragy explains how CRISPR gene editing in large animals offers exciting opportunities in biomedical ...
In early September, 15-year-old gene therapy developer Precision BioSciences devoted its entire two-hour R&D presentation to products in its pipeline that involve in vivo gene editing—therapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results